Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
105.60
+4.60 (4.55%)
Jul 21, 2026, 3:55 PM EDT - Market open
Dianthus Therapeutics Revenue
Dianthus Therapeutics had revenue of $463.00K in the quarter ending March 31, 2026, a decrease of -60.19%. This brings the company's revenue in the last twelve months to $1.34M, down -79.52% year-over-year. In the year 2025, Dianthus Therapeutics had annual revenue of $2.04M, down -67.35%.
Revenue (ttm)
$1.34M
Revenue Growth
-79.52%
P/S Ratio
4,149.48
Revenue / Employee
$14,522
Employees
92
Market Cap
5.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | -4.20M | -67.35% |
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 827.11M |
| Travere Therapeutics | 536.20M |
| Ligand Pharmaceuticals | 274.48M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 5.07M |
DNTH News
- 18 days ago - Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 22 days ago - Dianthus initiates EMERGE trial of claseprubart - TheFly
- 22 days ago - Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis - GlobeNewsWire
- 5 weeks ago - Dianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James - TheFly
- 5 weeks ago - Dianthus reports additional data from Part A of CAPTIVITY study - TheFly
- 5 weeks ago - Dianthus rises 7.7% - TheFly
- 5 weeks ago - Dianthus price target raised to $132 from $110 at Jefferies - TheFly
- 5 weeks ago - Dianthus falls -16.0% - TheFly